Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -692.83% is 86% below its 5-year average of -372.88%, around the middle of its 5-year range (-2410.99%–69.25%).
35.46% above its 12-month average of -1073.45%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -734.73%.
OPERATING MARGIN
-692.83%
OPERATING MARGIN AVG TTM
-1073.45%
OPERATING MARGIN AVG 3Y
-496.11%
OPERATING MARGIN AVG 5Y
-372.88%
OPERATING MARGIN AVG 10Y
-510.33%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+35.46%
CURRENT VS 3Y AVG
-39.65%
CURRENT VS 5Y AVG
-85.80%
CURRENT VS 10Y AVG
-35.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Alector, Inc.
Market Cap
$205.40M
Operating Margin
-692.83%
TTM Avg
-1073.45%
3Y Avg
-496.11%
5Y Avg
-372.88%
Market Cap
$203.22M
Operating Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.94M
Operating Margin
-566038.89%
TTM Avg
-577080.92%
3Y Avg
-336097.22%
5Y Avg
-224856.35%
Market Cap
$215.11M
Operating Margin
40.94%
TTM Avg
-5.20%
3Y Avg
-130.22%
5Y Avg
-446.71%
Market Cap
$215.30M
Operating Margin
6.67%
TTM Avg
9.41%
3Y Avg
-3.44%
5Y Avg
-14.56%
Market Cap
$218.58M
Operating Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.90%
5Y Avg
43.81%
Market Cap
$189.88M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$190.17M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$224.74M
Operating Margin
28.94%
TTM Avg
-2955.01%
3Y Avg
-29613.43%
5Y Avg
-19789.03%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $205.40M | -692.83% | -1073.45% | -496.11% | -372.88% |
| Electra Therapeutics Inc. (ETRA)vs › | $203.22M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | -566038.89% | -577080.92% | -336097.22% | -224856.35% |
| Compugen Ltd. (CGEN)vs › | $215.11M | 40.94% | -5.20% | -130.22% | -446.71% |
| Niagen Bioscience Inc (NAGE)vs › | $215.30M | 6.67% | 9.41% | -3.44% | -14.56% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.58M | 66.70% | 45.54% | 40.90% | 43.81% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $190.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Keros Therapeutics, Inc. (KROS)vs › | $224.74M | 28.94% | -2955.01% | -29613.43% | -19789.03% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
54.1%
Operating Margin
-692.8%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -734.73% |
| 2026-03-31 | -2410.99% |
| 2025-12-31 | -634.38% |
| 2025-09-30 | -1153.62% |
| 2025-06-30 | -433.55% |
| 2025-03-31 | -1216.52% |
| 2024-12-31 | -13.36% |
| 2024-09-30 | -315.70% |
| 2024-06-30 | -302.37% |
| 2024-03-31 | -275.01% |
| 2023-12-31 | -312.40% |
| 2023-09-30 | -555.31% |
| 2023-06-30 | -6.38% |
| 2023-03-31 | -302.83% |
| 2022-12-31 | -383.92% |
| 2022-09-30 | -321.49% |
| 2022-06-30 | 11.87% |
| 2022-03-31 | -180.29% |
| 2021-12-31 | -398.23% |
| 2021-09-30 | 69.25% |
| 2021-06-30 | -842.34% |
| 2021-03-31 | -1280.66% |
| 2020-12-31 | -1087.12% |
| 2020-09-30 | -910.38% |
| 2020-06-30 | -1469.68% |
| 2020-03-31 | -586.78% |
| 2019-12-31 | -538.94% |
| 2019-09-30 | -1266.65% |
| 2019-06-30 | -392.54% |
| 2019-03-31 | -370.40% |
| 2018-12-31 | -207.95% |
| 2018-09-30 | -258.57% |
| 2018-06-30 | -172.05% |
| 2018-03-31 | -187.50% |
| 2017-12-31 | -320.59% |
| 2017-09-30 | -6595.42% |
| 2017-06-30 | -2443.79% |
| 2017-03-31 | -2443.79% |
